ImmunityBio Requests An Urgent Meeting With FDA To Address The Change In The Agency’S Unambiguous Guidance On Jan 2025 To Submit A SBLA For NMIBC BCG Unresponsive Papillary Disease, Following An Inconsistent Refusal To File Letter On May 2, 2025
May 5 (Reuters) - Immunitybio Inc IBRX.O:
IMMUNITYBIO REQUESTS AN URGENT MEETING WITH FDA TO ADDRESS THE CHANGE IN THE AGENCY’S UNAMBIGUOUS GUIDANCE ON JAN 2025 TO SUBMIT A SBLA FOR NMIBC BCG UNRESPONSIVE PAPILLARY DISEASE, FOLLOWING AN INCONSISTENT REFUSAL TO FILE LETTER ON MAY 2, 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.